BRPI0414553A - previsão do resultado de tratamento contra o cáncer de mama - Google Patents

previsão do resultado de tratamento contra o cáncer de mama

Info

Publication number
BRPI0414553A
BRPI0414553A BRPI0414553-4A BRPI0414553A BRPI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A BR PI0414553 A BRPI0414553 A BR PI0414553A
Authority
BR
Brazil
Prior art keywords
breast cancer
tamoxifen
response
prediction
cases
Prior art date
Application number
BRPI0414553-4A
Other languages
English (en)
Inventor
Xiao-Jun Ma
Mark G Erlander
Dennis C Sgroi
Edward Enright
Original Assignee
Arcturus Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/727,100 external-priority patent/US7504214B2/en
Priority claimed from US10/773,761 external-priority patent/US9856533B2/en
Application filed by Arcturus Bioscience Inc filed Critical Arcturus Bioscience Inc
Publication of BRPI0414553A publication Critical patent/BRPI0414553A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"PREVISãO DO RESULTADO DE TRATAMENTO CONTRA O CáNCER DE MAMA". Métodos e composições são providos para a identificação de assinaturas de expressão em casos de câncer de mama ER+, onde as assinaturas estão correlacionadas com a resposta, ou falta da mesma, ao tratamento com tamoxifeno ou outro agente antiestrogênico contra câncer de mama. Os perfis de assinatura são identificados com base na amostragem de amostras de tecido de mama de referência a partir de casos independentes de câncer de mama e provêem um conjunto confiável de critérios moleculares para prever a eficácia de tratamento de um indivíduo com câncer de mama com tamoxifeno ou outro agente antiestrogênico contra câncer de marna. Métodos adicionais e composições são providos para prever a resposta a tamoxifeno ou outro agente antiestrogênico contra câncer de mama em casos de câncer de mama por uso de biomarcadores múltiplos. Dois biomarcadores mostram uma expressão aumentada correlacionada com a resposta a tamoxifeno enquanto dois outros biomarcadores mostram expressão diminuída correlacionada com a resposta a tamoxifeno.
BRPI0414553-4A 2003-09-19 2004-09-17 previsão do resultado de tratamento contra o cáncer de mama BRPI0414553A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50408703P 2003-09-19 2003-09-19
US10/727,100 US7504214B2 (en) 2003-09-19 2003-12-02 Predicting outcome with tamoxifen in breast cancer
US10/773,761 US9856533B2 (en) 2003-09-19 2004-02-06 Predicting breast cancer treatment outcome
US54719904P 2004-02-23 2004-02-23
PCT/US2004/030789 WO2005028681A1 (en) 2003-09-19 2004-09-17 Predicting breast cancer treatment outcome

Publications (1)

Publication Number Publication Date
BRPI0414553A true BRPI0414553A (pt) 2006-11-07

Family

ID=34382172

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414553-4A BRPI0414553A (pt) 2003-09-19 2004-09-17 previsão do resultado de tratamento contra o cáncer de mama

Country Status (7)

Country Link
US (1) US20060154267A1 (pt)
EP (1) EP1670946B1 (pt)
JP (1) JP2007505630A (pt)
AU (1) AU2004274973A1 (pt)
BR (1) BRPI0414553A (pt)
CA (1) CA2539107A1 (pt)
WO (1) WO2005028681A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
DE602005015687D1 (de) 2004-03-02 2009-09-10 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
JP2008534002A (ja) * 2005-04-01 2008-08-28 エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド 乳癌の分類に関する材料および方法
US20070134688A1 (en) * 2005-09-09 2007-06-14 The Board Of Regents Of The University Of Texas System Calculated index of genomic expression of estrogen receptor (er) and er-related genes
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
US20090326333A1 (en) * 2005-12-09 2009-12-31 Goetz Matthew P Assessing outcomes for breast cancer patients
JP5554927B2 (ja) 2006-02-15 2014-07-23 ホロジック， インコーポレイテッド トモシンセシスシステムを使用した乳房バイオプシおよびニードル位置特定
JP2007267700A (ja) * 2006-03-31 2007-10-18 Kochi Univ Ｈｏｘｂ１３遺伝子のメチル化を指標とする腎細胞癌を含む悪性腫瘍の判定方法
EP2021803B1 (en) * 2006-05-18 2012-02-08 Mayo Foundation for Medical Education and Research Assessing outcomes for breast cancer patients
EP1873258A1 (en) 2006-06-26 2008-01-02 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in breast cancer
EP2090588A4 (en) 2006-10-23 2010-04-07 Neocodex S L IN VITRO PROCEDURE FOR THE PROGNOSIS AND / OR DIAGNOSIS OF OVER SENSITIVITY TO ESTROGENIC OR SUBSTANCES WITH ESTROGENIC EFFECT
WO2008133493A1 (en) * 2007-04-27 2008-11-06 Erasmus University Medical Center Rotterdam Prediction of responsiveness to anti-estrogen treatment in breast cancer
ES2618353T3 (es) * 2007-09-06 2017-06-21 Biotheranostics, Inc. Clasificación de tumores y pronóstico del cáncer de mama
WO2009067611A1 (en) * 2007-11-20 2009-05-28 University Of South Florida Seven gene breast cancer predictor
US10295540B1 (en) * 2009-02-13 2019-05-21 Cancer Genetics, Inc. Systems and methods for phenotypic classification using biological samples of different sample types
US20100316567A1 (en) 2009-06-12 2010-12-16 Weichert Jamey P Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
GB0916124D0 (en) 2009-09-15 2009-10-28 Univ Cardiff Method and kit for the classification and prognosis of wounds
CN102481146B (zh) 2009-10-08 2016-08-17 霍罗吉克公司 乳房的穿刺活检系统及其使用方法
EP2484760B1 (en) * 2010-04-22 2015-10-14 Toray Industries, Inc. METHOD FOR PREPARING aRNA.
CN103998064A (zh) 2010-12-09 2014-08-20 生物诊断治疗公司 治疗后的乳腺癌预后
GB201021182D0 (en) 2010-12-14 2011-01-26 Univ Cardiff Methdo and kit for the classification and prognosis of chronic wounds
CA2824877A1 (en) * 2011-01-28 2012-08-02 Biodesix, Inc. Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
GB201103898D0 (en) 2011-03-08 2011-04-20 Univ Cardiff Molecular targets for healing or treating wounds
CN110353709A (zh) 2011-03-08 2019-10-22 霍洛吉克公司 双能和/或造影增强乳房成像的系统和方法
JP2015504510A (ja) * 2011-11-04 2015-02-12 インヴィヴィス，エスエーエス 抗エストロゲン剤の効果予測バイオマーカーのアッセイ
KR102109588B1 (ko) 2011-11-27 2020-05-12 홀로직, 인크. 유방 조직 이미지를 프로세싱하고, 디스플레잉하고, 네비게이팅하기 위한 방법
CN104135935A (zh) 2012-02-13 2014-11-05 霍罗吉克公司 用于利用合成图像数据导航层析堆的系统和方法
JP6388347B2 (ja) 2013-03-15 2018-09-12 ホロジック, インコーポレイテッドHologic, Inc. 腹臥位におけるトモシンセシス誘導生検
WO2014149554A1 (en) 2013-03-15 2014-09-25 Hologic, Inc. System and method for navigating a tomosynthesis stack including automatic focusing
WO2015038682A1 (en) 2013-09-11 2015-03-19 bio Theranostics, Inc. Predicting breast cancer recurrence
ES2943561T3 (es) 2014-02-28 2023-06-14 Hologic Inc Sistema y método para generar y visualizar bloques de imagen de tomosíntesis
JP6517933B2 (ja) * 2015-06-24 2019-05-22 株式会社日立製作所 検査システム、検査装置、及び検査方法
US11530448B2 (en) 2015-11-13 2022-12-20 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
EP3387168B1 (en) 2015-12-07 2021-05-12 Ontario Institute for Cancer Research (OICR) Gene signature of residual risk following endocrine treatment in early breast cancer
JP7169986B2 (ja) 2017-03-30 2022-11-11 ホロジック， インコーポレイテッド オブジェクトグリッド増強を用いて高次元画像データから低次元画像データを合成するためのシステムおよび方法
US11399790B2 (en) 2017-03-30 2022-08-02 Hologic, Inc. System and method for hierarchical multi-level feature image synthesis and representation
KR102397337B1 (ko) * 2017-05-29 2022-05-12 출라폰 파운데이션 간세포 암종(hcc) 또는 담관암종(cca)을 갖는 개체의 생존결과를 예측하는 방법
MX2021001857A (es) * 2018-08-17 2021-10-13 Genentech Inc Star Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.
AU2019349684B2 (en) * 2018-09-24 2025-04-10 Hologic, Inc. Breast mapping and abnormality localization
US12505645B2 (en) 2020-03-27 2025-12-23 Hologic, Inc. Systems and methods for correlating regions of interest in multiple imaging modalities
CN115348837A (zh) 2020-03-27 2022-11-15 豪洛捷公司 用于在多种成像模态中识别关注区域的系统和方法
US12254586B2 (en) 2021-10-25 2025-03-18 Hologic, Inc. Auto-focus tool for multimodality image review
WO2023097279A1 (en) 2021-11-29 2023-06-01 Hologic, Inc. Systems and methods for correlating objects of interest

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002316251A1 (en) * 2001-06-18 2003-01-02 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US7622260B2 (en) * 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US7504214B2 (en) * 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer

Also Published As

Publication number Publication date
EP1670946A1 (en) 2006-06-21
AU2004274973A1 (en) 2005-03-31
WO2005028681A1 (en) 2005-03-31
CA2539107A1 (en) 2005-03-31
US20060154267A1 (en) 2006-07-13
JP2007505630A (ja) 2007-03-15
EP1670946B1 (en) 2012-11-07

Similar Documents

Publication Publication Date Title
BRPI0414553A (pt) previsão do resultado de tratamento contra o cáncer de mama
Lo et al. Epigenomics and breast cancer
EP2037967A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING OR REDUCING HAIR LOSS, ACNE, ROSACEA, PROSTATE CANCER AND BPH
NZ593225A (en) Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
TW200512298A (en) Method of diagnosing breast cancer
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
EP2392678A3 (en) Prognosis prediction for colorectal cancer
CU23784B7 (es) Bencimidazoles sustituidos como inhibidores de cinasa
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
BRPI0701433A (pt) uso de uma composição cosmética, processo para melhorar a cor das fibras queratìnicas tingidas artificialmente, processo de coloração e agente de coloração multicomponente ou kit
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
BRPI1007048A2 (pt) método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
BRPI0417903A (pt) método de melhorar a detecção de sinal de um componente de parede celular de células
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
Fasching et al. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
MX2009005941A (es) Ensayos de diagnostico complementario para terapia de cancer.
ATE496635T1 (de) Verfahren und zusammensetzungen zur hemmung, prävention oder verringerung des tumorzellwachstums bei patienten, die gegen die antineoplastischen wirkungen einer antiöstrogen- therapie resistent sind
WO2010033773A3 (en) Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways
Cheng et al. Interplay between menin and Dnmt1 reversibly regulates pancreatic cancer cell growth downstream of the Hedgehog signaling pathway
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011.